Stroke:血栓长度对动脉内血栓抽吸结局的影响!

2017-06-09 xing.T MedSci原创

缺血性脑卒中患者症状性血栓越长,其90天的临床结局越差,但采用血栓抽吸可能比单独进行IV r-tPA获得更大的效益。

增加血栓长度(TL)会阻碍静脉溶栓后的血管再通。近日,卒中领域权威杂志Stroke上发表了一篇研究文章,研究人员试图明确在较长的TL中血栓抽吸是否比IV r-tPA(重组组织型纤溶酶原激活物)有更大的临床受益。

THERAPY 是一个在TL超过8cm的大血管卒中患者中进行的比较血栓抽吸加IV r-tPA与单纯IV r-tPA的前瞻性随机试验。在这项研究的事后分析中,研究人员利用单变量、多变量和乘法相互作用分析评价了TL与试验终点以及潜在血管内治疗效果效应之间的相关性。

该研究有108例患者的LT数据可用(28%为颈内动脉,62%为M1,10%为M2)。中位TL为14mm(四分位间距范围为9.7-19.5mm)。更长的TL与更坏的结局相关(90天改良Rankin评分:TL每增加5mm比值比为1.24;95%可信区间为1.04-1.52;P=0.02),即使将关键的结局预测因子调整后(调整后的P=0.004)。较长的TL也与更严重的不良事件(校正p=0.01)、更多有症状性出血(校正p=0.03)和死亡率增加(校正p=0.01)相关。在TL和血管造影再灌注(脑缺血改良的溶栓为2b-3)之间没有观察到显著的相关性,但更长的TL与较长的介入操作时间相关(ρ=0.36;P=0.045)。TL增加与更大的血栓抽吸治疗效果相关(相互作用P=0.03)。这可能是增加TL对IV r-tPA治疗患者(ρ=0.39;P=0.01)90天改良Rankin量表评分一个潜在的强大不利影响,相比于动脉内治疗患者(ρ=0.20;P=0.165)。

缺血性脑卒中患者症状性血栓越长,其90天的临床结局越差,但采用血栓抽吸可能比单独进行IV r-tPA获得更大的效益。

原始出处:

Albert J. Yoo,et al. Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial.Stroke. 2017. https://doi.org/10.1161/STROKEAHA.116.016253

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-11 meiliwuxian

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 林3301

    推广起来还是药物较为实际吧?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 三生有幸9135

    学习一下谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 changjiu

    看看,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1641498, encodeId=3c1f1641498fe, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Fri May 18 05:58:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=209221, encodeId=7cda209221d4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Jun 11 07:22:37 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208713, encodeId=05aa208e13a1, content=推广起来还是药物较为实际吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Jun 09 21:28:22 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208688, encodeId=dbf520868818, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 09 19:49:36 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208683, encodeId=40de208683b3, content=看看,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Jun 09 19:31:55 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208672, encodeId=b1292086e2f1, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 09 19:14:12 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 1e0f8808m18(暂无匿称)

    好文章,学习了。

    0